For decades, medical device manufacturers selling into the US market worked under two separate quality system frameworks: 21 CFR Part 820 for the FDA and ISO 13485:2016 for nearly every other regulator in the world. As of February 2, 2026, that split is gone. The FDA’s Quality Management System Regulation (QMSR) replaces Part 820 and incorporates ISO 13485:2016 directly by reference, and the agency has also retired the inspection model that manufacturers built their audit programs around for years. If your quality system, your inspection readiness, or your regulatory strategy still assumes the old rules, it’s time for an update.
What Is the FDA QMSR and What Changed on February 2, 2026
The FDA finalized the QMSR in early 2024 and set a two year implementation window, which closed on February 2, 2026. From that date forward, the agency treats ISO 13485:2016 as the baseline quality management system standard for devices sold in the US, with a small set of FDA specific additions layered on top. The FDA has stated that ISO 13485 requirements are substantially similar to the former Part 820 requirements and offer a comparable level of assurance around device safety and effectiveness.
The same date marked a second, less publicized shift. The FDA stopped using the Quality System Inspection Technique (QSIT), the framework investigators had followed since the 1990s, and moved to a new compliance program built specifically for QMSR inspections. Two legacy inspection documents, covering general device manufacturer inspections and PMA pre and post-market inspections, were formally withdrawn.
Why the FDA Moved to ISO 13485
The rationale is largely practical. Most manufacturers selling into the EU, UK, Canada, or other major markets were already certified to ISO 13485:2016 to satisfy those regulators, which meant many US based companies were effectively running two overlapping quality systems side by side: one to satisfy Part 820 language, and one to satisfy ISO 13485 clause structure. Aligning the FDA’s own regulation with the international standard reduces that duplication and brings the US in step with the quality system expectations used almost everywhere else in the world.
For manufacturers that export internationally and already hold ISO 13485 certification, this is good news in principle. It does not mean the FDA has stepped back from oversight. The agency has been clear that its own statutory obligations, including complaint handling, Medical Device Reporting (MDR) under 21 CFR Part 803, and records accessibility, remain fully enforceable regardless of the shift to ISO 13485 language.
What the QMSR Transition Does Not Change
It helps to be precise about what QMSR does and does not change, since a lot of confusion has understandably followed this transition.
- Device classification (Class I, II, III) and the associated premarket pathways, 510(k) and PMA, are unaffected.
- Medical Device Reporting obligations under Part 803 continue to apply in full.
- Complaint handling requirements remain enforceable and are a common inspection focus area.
- Records must remain accessible to investigators, including records created before February 2, 2026. The FDA has indicated it may review pre transition documentation as part of assessing ongoing compliance.
- Establishment registration, device listing, and labeling requirements under Parts 807 and 801 are untouched by QMSR.
How Manufacturers Should Prepare for QMSR
For companies already certified to ISO 13485:2016 through a notified body or certification scheme, the transition mainly changes documentation language and inspection expectations rather than the substance of the quality system itself. Even so, a few areas deserve direct attention.
1. Run a Gap Assessment Against the New Inspection Model
QSIT organized inspections around four subsystems: management controls, design controls, corrective and preventive action (CAPA), and production and process controls. The new compliance program, 7382.850, follows a different structure aligned to ISO 13485 clauses. Even a quality system that was fully QSIT compliant may present differently to an investigator working from the new program, so it is worth walking through the new inspection logic before, not during, your next audit.
2. Confirm FDA Specific Requirements Are Still Documented Separately
ISO 13485:2016 does not include every obligation the FDA enforces. Complaint handling triggers for MDR reporting, specific recordkeeping timeframes, and certain US only regulatory submissions are FDA additions layered on top of the ISO baseline. These need to be traceable in your quality system documentation even though they will not appear in the ISO standard itself.
3. Make Sure Historical Records Hold Up
Because investigators may review documentation created before the QMSR effective date, records from your prior Part 820 system should be organized and defensible under the new framework, not just archived. This is especially relevant for design history files and CAPA records tied to devices still on the market.
Where This Leaves ISO 13485 Certified Manufacturers
If your quality management system is already built around ISO 13485:2016, and certified as such, you are closer to QMSR readiness than a company still operating a purely Part 820 style system. That head start does not remove the need for a documented gap assessment. Investigators are working from a new compliance program, historical records need to hold up under new scrutiny, and FDA specific obligations still need explicit traceability inside an ISO structured quality system.
This is also where device design and development work benefits from starting on the right foot. A device developed against ISO 13485 aligned design controls from day one avoids the retrofitting that companies transitioning mid program are now facing across their existing product lines.
The Bottom Line on FDA QMSR
The QMSR transition is the most significant change to US medical device quality system regulation in nearly three decades. It brings the FDA in line with the standard most of the rest of the world has used for years, but it does not loosen oversight. Manufacturers should treat February 2, 2026 as a floor, not a finish line: a documented gap assessment against the new inspection program, careful attention to FDA specific requirements that sit outside the ISO standard, and a clear-eyed review of historical records are the practical next steps regardless of how mature your existing quality system is.
Phoenix Biomed is ISO 13485:2016 and MDR certified, and works with manufacturers on device design, development, and manufacturing under both frameworks. If you are assessing what the QMSR transition means for your own quality system or an upcoming product line, our team can help walk through it.